0000950170-24-063707.txt : 20240523 0000950170-24-063707.hdr.sgml : 20240523 20240522195454 ACCESSION NUMBER: 0000950170-24-063707 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240521 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240523 DATE AS OF CHANGE: 20240522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 24974944 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 vktx-20240521.htm 8-K 8-K
false000160767800016076782024-05-212024-05-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 21, 2024

 

Viking Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-37355

46-1073877

(State or Other Jurisdiction of

Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (858) 704-4660

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.00001 per share

VKTX

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 21, 2024, Viking Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the Viking Therapeutics, Inc. 2024 Equity Incentive Plan (the “2024 EIP”) and the Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”). The 2024 EIP and the 2024 ESPP were previously approved by the Board of Directors of the Company, subject to stockholder approval.

 

The 2024 EIP and the 2024 ESPP each became effective on May 21, 2024 upon stockholder approval at the Annual Meeting. More complete summaries of the terms of the 2024 EIP and the 2024 ESPP are set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 5, 2024 (the “Proxy Statement”) under the sections entitled “Proposal No. 4 Approval of our 2024 Equity Incentive Plan” and in “Proposal No. 5 Approval of our 2024 Employee Stock Purchase Plan,” respectively, which description and text are incorporated herein by reference.

 

The foregoing description of the terms of the 2024 EIP and the 2024 ESPP and the descriptions thereof incorporated by reference from the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2024 EIP and the 2024 ESPP, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On May 21, 2024, the Company held the Annual Meeting. Of the 110,217,994 shares of the Company’s common stock outstanding as of March 28, 2024, the record date for the Annual Meeting, 88,199,492 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 80.1% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.

 

At the Annual Meeting, the Company’s stockholders considered five proposals, each of which is described in more detail in the Company’s Proxy Statement.

 

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

 

Proposal No. 1. To elect the following nominees as Class III directors to serve until the Company’s 2027 annual meeting of stockholders or until such director’s respective successor is duly elected and qualified:

 

 

 

 

 

 

 

Director Nominee

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Brian Lian, Ph.D.

 

50,502,615

 

17,436,415

 

20,260,462

Lawson Macartney, Ph.D.

 

22,267,255

 

45,671,775

 

20,260,462

 

As a result, the Company’s stockholders voted to elect Brian Lian, Ph.D. and Lawson Macartney, Ph.D. as Class III directors to serve until the Company’s 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified.

 

Proposal No. 2. To ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2024:

 

 

 

 

 

Votes For

 

Votes Against

 

Abstentions

87,382,144

 

743,579

 

73,767

 

As a result, the Company’s stockholders voted to ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2024.

 

Proposal No. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement:

 

 

 

 

 

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

63,234,707

 

4,510,461

 

193,862

 

20,260,462

 

As a result, the Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

 

 

Proposal No. 4. To approve the 2024 EIP:

 

 

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

48,547,615

 

19,279,010

 

112,405

 

20,260,462

 

As a result, the Company’s stockholders voted to approve the 2024 EIP.

 

Proposal No. 5. To approve the 2024 ESPP:

 

 

 

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

67,119,655

 

734,042

 

85,333

 

20,260,462

 

As a result, the Company’s stockholders voted to approve the 2024 ESPP.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

Exhibit No.

 

Description

10.1

 

Viking Therapeutics, Inc. 2024 Equity Incentive Plan (previously filed on May 22, 2024 as Exhibit 4.2 to the Registrant’s Registration Statement on Form S-8 and incorporated herein by reference).

10.2

 

Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan (previously filed on May 22, 2024 as Exhibit 4.6 to the Registrant’s Registration Statement on Form S-8 and incorporated herein by reference).

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Viking Therapeutics, Inc.

 

Date: May 22, 2024

By:

 /s/ Brian Lian, Ph.D.

 

Brian Lian, Ph.D.

 

President and Chief Executive Officer

 

(Principal Executive Officer)

 

 EX-101.SCH 2 vktx-20240521.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 21, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 21, 2024
Entity Registrant Name Viking Therapeutics, Inc.
Entity Central Index Key 0001607678
Entity Emerging Growth Company false
Entity File Number 001-37355
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-1073877
Entity Address, Address Line One 9920 Pacific Heights Blvd
Entity Address, Address Line Two Suite 350
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 704-4660
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol VKTX
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports vktx-20240521.htm vktx-20240521.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vktx-20240521.htm": { "nsprefix": "vktx", "nsuri": "http://vikingtherapeutics.com/20240521", "dts": { "inline": { "local": [ "vktx-20240521.htm" ] }, "schema": { "local": [ "vktx-20240521.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_ca79174a-ff27-4b07-9367-45623b4eea15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vktx-20240521.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ca79174a-ff27-4b07-9367-45623b4eea15", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "vktx-20240521.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vikingtherapeutics.com/20240521/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-063707-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-063707-xbrl.zip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vktx-20240521_htm.xml IDEA: XBRL DOCUMENT 0001607678 2024-05-21 2024-05-21 false 0001607678 8-K 2024-05-21 Viking Therapeutics, Inc. DE 001-37355 46-1073877 9920 Pacific Heights Blvd Suite 350 San Diego CA 92121 858 704-4660 false false false false Common Stock, par value $0.00001 per share VKTX NASDAQ false